ArticlebioRxiv : the preprint server for biology2026
Localized Rigidification and Allosteric Modulation Mechanisms of SARS-CoV-2 Spike Neutralization by Class 3 and Class 4 Antibodies at Atomic Resolution: An Integrated Computational Study of Binding, Dynamics, and Allostery.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The relentless evolution of SARS-CoV-2 and the emergence of highly antibody-evasive variants underscore the need to decipher the molecular principles that govern antibody neutralization breadth and resilience. In this study, we employ an integrated computational framework combining structural analysis, conformational dynamics, mutational scanning, binding energetics, and allosteric network modeling to dissect the mechanistic signatures of class 3 and class 4 antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Through comprehensive analysis of antibody-RBD complexes including individual antibodies (COV2-3835, COV2-3891, COV2-3906) and synergistic dual-antibody pairs we uncover a fundamental mechanistic dichotomy that distinguishes these two antibody classes and explains their differential patterns of neutralization potency, breadth, and resilience to viral escape. Our analysis reveals that class 3 antibodies achieve neutralization with mechanical perturbation strictly confined to the binding interface. In contrast, class 4 antibodies employ a long-range allosteric destabilization mechanism, anchoring to a structurally rigid hydrophobic core and establishing a mechanical conduit through the β-sheet core that transmits conformational changes. Mutational scanning and rigorous energetic analysis reveal fundamentally different vulnerability landscapes: class 4 epitopes are defined by an immutable hydrophobic core that is exquisitely sensitive to mutation yet evolutionarily constrained across sarbecoviruses, explaining their ultra-broad binding and limited escape potential. Class 3 epitopes exhibit a plastic periphery with a conserved anchor and variable sensitivity in peripheral regions, creating multiple escape pathways. These predictions show excellent agreement with experimental deep mutational scanning data, validating our computational approach and establishing a quantitative framework for predicting immune escape. Allosteric network analysis identifies the β-sheet core as the critical communication conduit for class 4 antibodies, with specific residues serving as essential hubs that connect the hydrophobic core to the RBM loop. The convergence of high communication centrality with extreme perturbation sensitivity at these positions establishes them as the most critical allosteric hotspots, essential for function and resistant to mutation. The proposed multi-pronged computational framework provides a generalizable approach for understanding antibody neutralization mechanisms and predicting immune escape across diverse viral targets, with implications for the rational design of next-generation antibody therapeutics that balance potency, breadth, and resilience.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.